Ionis Pharmaceuticals/$IONS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Ticker
$IONS
Sector
Primary listing
Employees
1,069
Headquarters
Website
IONS Metrics
BasicAdvanced
$9.2B
-
-$1.73
0.25
-
Price and volume
Market cap
$9.2B
Beta
0.25
52-week high
$57.92
52-week low
$23.95
Average daily volume
2.5M
Financial strength
Current ratio
2.874
Quick ratio
2.612
Long term debt to equity
210.706
Total debt to equity
310.285
Interest coverage (TTM)
-2.92%
Profitability
EBITDA (TTM)
-255.171
Gross margin (TTM)
5.30%
Net profit margin (TTM)
-28.43%
Operating margin (TTM)
-28.30%
Effective tax rate (TTM)
2.21%
Revenue per employee (TTM)
$880,000
Management effectiveness
Return on assets (TTM)
-5.88%
Return on equity (TTM)
-59.91%
Valuation
Price to revenue (TTM)
9.507
Price to book
14.49
Price to tangible book (TTM)
14.49
Price to free cash flow (TTM)
-31.753
Free cash flow yield (TTM)
-3.15%
Free cash flow per share (TTM)
-1.811
Growth
Revenue change (TTM)
16.02%
Earnings per share change (TTM)
-31.79%
3-year revenue growth (CAGR)
3.60%
10-year revenue growth (CAGR)
11.71%
3-year earnings per share growth (CAGR)
105.38%
10-year earnings per share growth (CAGR)
24.66%
What the Analysts think about IONS
Analyst ratings (Buy, Hold, Sell) for Ionis Pharmaceuticals stock.
Bulls say / Bears say
The U.S. FDA approved Dawnzera (donidalorsen) on August 21, 2025 as the first RNA-targeted prophylactic for hereditary angioedema, marking Ionis’ second independent commercial launch and expanding its direct revenue portfolio (Reuters).
Ionis’ Q2 2025 revenue doubled year-over-year to $452 million, beating consensus, driven by strong TRYNGOLZA uptake and R&D collaborations, prompting management to raise full-year 2025 guidance to $825–850 million (Investing.com).
Biogen is advancing salanersen (ION306/BIIB115) into registrational Phase 3 studies based on positive interim Phase 1 data demonstrating a 70% reduction in neurofilament and meaningful motor function gains in SMA patients, underscoring the pipeline’s high-impact potential (Ionis).
R&D revenue in Q2 2025 surged 128% year-over-year to $349 million was driven by a one-time $280 million upfront license payment from Ono for sapablursen, highlighting collaboration revenue volatility that may not recur in future quarters (Nasdaq).
SG&A expenses jumped 42% year-over-year in Q2 2025 to support the launches of TRYNGOLZA and WAINUA, contributing to an 8% rise in adjusted operating costs and pressuring margins absent sustained top-line growth (Nasdaq).
Excluding one-off milestones, R&D revenues declined 7% to $56 million in Q1 2025, indicating potential contraction in underlying collaboration income once upfront payments taper off (Zacks).
Data summarised monthly by Lightyear AI. Last updated on 30 Aug 2025.
IONS Financial Performance
Revenues and expenses
IONS Earnings Performance
Company profitability
IONS News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ionis Pharmaceuticals stock?
Ionis Pharmaceuticals (IONS) has a market cap of $9.2B as of September 03, 2025.
What is the P/E ratio for Ionis Pharmaceuticals stock?
The price to earnings (P/E) ratio for Ionis Pharmaceuticals (IONS) stock is 0 as of September 03, 2025.
Does Ionis Pharmaceuticals stock pay dividends?
No, Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders as of September 03, 2025.
When is the next Ionis Pharmaceuticals dividend payment date?
Ionis Pharmaceuticals (IONS) stock does not pay dividends to its shareholders.
What is the beta indicator for Ionis Pharmaceuticals?
Ionis Pharmaceuticals (IONS) has a beta rating of 0.25. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.